Market Overview

Mylan Launches Generic Version of Qualaquin Caps

Share:
Related MYL
Tracking The Busy June PDUFA Calendar
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quinine Sulfate Capsules USP, 324 mg. This product is the generic version of Mutual Pharmaceutical Company, Inc.'s Qualaquin^® Capsules, and is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria.(1)

Quinine Sulfate Capsules USP, 324 mg, had U.S. sales of approximately $31.9 million for the 12 months ending Sept. 30, 2012, according to IMS Health. Mylan has begun shipping this product.

Posted-In: News

 

Related Articles (MYL)

View Comments and Join the Discussion!